Holoxan Innrennslisstofn, lausn 500 mg Ісландія - ісландська - LYFJASTOFNUN (Icelandic Medicines Agency)

holoxan innrennslisstofn, lausn 500 mg

baxter medical ab* - ifosfamidum inn - innrennslisstofn, lausn - 500 mg

Holoxan Innrennslisstofn, lausn 2000 mg Ісландія - ісландська - LYFJASTOFNUN (Icelandic Medicines Agency)

holoxan innrennslisstofn, lausn 2000 mg

baxter medical ab* - ifosfamidum inn - innrennslisstofn, lausn - 2000 mg

Holoxan Innrennslisstofn, lausn 1000 mg Ісландія - ісландська - LYFJASTOFNUN (Icelandic Medicines Agency)

holoxan innrennslisstofn, lausn 1000 mg

baxter medical ab* - ifosfamidum inn - innrennslisstofn, lausn - 1000 mg

Sotalol Viatris (Sotalol Mylan) Tafla 40 mg Ісландія - ісландська - LYFJASTOFNUN (Icelandic Medicines Agency)

sotalol viatris (sotalol mylan) tafla 40 mg

viatris limited - sotalolum hýdróklóríð - tafla - 40 mg

Sotalol Viatris (Sotalol Mylan) Tafla 80 mg Ісландія - ісландська - LYFJASTOFNUN (Icelandic Medicines Agency)

sotalol viatris (sotalol mylan) tafla 80 mg

viatris limited - sotalolum hýdróklóríð - tafla - 80 mg

Braftovi Європейський Союз - ісландська - EMA (European Medicines Agency)

braftovi

pierre fabre medicament - encorafenib - melanoma; colorectal neoplasms - Æxlishemjandi lyf - encorafenib is indicated:in combination with binimetinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutationin combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, who have received prior systemic therapy.

Tafinlar Європейський Союз - ісландська - EMA (European Medicines Agency)

tafinlar

novartis europharm limited - dabrafenib mesilate - melanoma - Æxlishemjandi lyf - melanomadabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation (see sections 4. 4 og 5. viðbótar meðferð melanomadabrafenib ásamt trametinib er ætlað til viðbótar meðferð fullorðinn sjúklinga með stigi iii húðkrabbanum með meÐferÐ v600 stökkbreyting, eftir fylltu brottnám. non-small cell lung cancer (nsclc)dabrafenib in combination with trametinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a braf v600 mutation.

Kisplyx Європейський Союз - ісландська - EMA (European Medicines Agency)

kisplyx

eisai gmbh - lenvatinib mesilat - krabbamein, nýrnafrumur - Æxlishemjandi lyf - kisplyx is indicated for the treatment of adults with advanced renal cell carcinoma (rcc):in combination with pembrolizumab, as first-line treatment (see section 5. in combination with everolimus, following one prior vascular endothelial growth factor (vegf)-targeted therapy.

Lenvima Європейський Союз - ісландська - EMA (European Medicines Agency)

lenvima

eisai gmbh - lenvatinib mesilat - skjaldkirtilsæxli - Æxlishemjandi lyf - lenvima er ætlað eitt og sér fyrir meðferð fullorðinn sjúklinga með versnandi, á staðnum háþróaður eða sjúklingum, þroskuð (papillary/tíðahvörf/hürthle klefi) skjaldkirtilskrabbamein (a), svarar til geislavirk joð (hin). lenvima er ætlað eitt og sér fyrir meðferð fullorðinn sjúklinga með langt eða unresectable lifrarfrumukrabbamein (akkeri) sem hafa fengið nei áður en almenna meðferð.

GHRYVELIN (previously Macimorelin Aeterna Zentaris) Європейський Союз - ісландська - EMA (European Medicines Agency)

ghryvelin (previously macimorelin aeterna zentaris)

atnahs pharma netherlands b.v. - macimorelin myndir - greiningaraðferðir, annarra - macimorelin - Þetta lyf er eingöngu ætlað til greiningar.  ghryvelin is indicated for the diagnosis of growth hormone deficiency (ghd) in adults.